BRAF and thyroid cancer: Moreover, vemurafenib-treated BRAF V600E-positive PTC cells exhibited an increased apoptosis level [132], whereas ascorbic acid (vitamin C) was found to sensitize BRAF V600E-positive thyroid cancer cells to this agent [133].